Latest news with #TMP-301
Yahoo
25-03-2025
- Business
- Yahoo
Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder
Tokyo, Japan and Cambridge, UK, 25 March 2025 – Nxera Pharma Co., Ltd. ('Nxera' or 'the Company'; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a potent, selective and orally available mGluR5 negative allosteric modulator (NAM), for the treatment of alcohol use disorder (Clinical Trial ID: NCT06648655). The full announcement from Tempero Bio can be found by clicking here, in which Tempero Bio also announces the close of a $70 million financing, the proceeds of which will be used to advance TMP-301 through the Phase 2 trial for alcohol use disorder and a second Phase 2 trial in cocaine use disorder planned to start over the next year. The funds will also be used by Tempero Bio to conduct Phase 3-enabling activities for TMP-301 and preclinical studies for additional indications and formulations. The Phase 2 study initiated will assess the safety, tolerability and effect on alcohol use of TMP-301 compared to placebo in patients with alcohol use disorder. Matt Barnes, EVP, President of Nxera Pharma UK and Head of R&D, commented: 'We are excited to see another program originating from our NxWave™ discovery platform advancing into the next stage of clinical development, as our partner Tempero Bio progresses TMP-301 to a Phase 2 trial for alcohol use disorder. This asset is another example highlighting the strength of our NxWave™ platform to continue delivering innovative candidates for further development. We are expecting an important year ahead across both our partnered and inhouse pipelines, with key data readouts anticipated from multiple trials as well as several new trials due to start.' Tempero Bio was created in 2020 by the venture firm Aditum Bio to advance the clinical development of a portfolio of potent, orally available metabotropic glutamate receptor 5 (mGluR5) NAMs, including TMP-301, discovered by Nxera and in development for substance use disorders. Under the terms of the 2020 agreement, Tempero Bio acquired exclusive global rights to Nxera's portfolio of mGluR5 NAM candidates. In return, Nxera received a strategic equity stake in Tempero Bio and is eligible to receive future success-based development and commercial milestone payments plus tiered royalties from any future product sales. There is no milestone payment payable by Tempero Bio to Nxera associated with the start of the Phase 2 trial. Nxera will disclose if a milestone event is reached that results in a material payment from Tempero Bio to Nxera. –END– About Nxera PharmaNxera Pharma is a technology powered biopharma company, in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. In addition to several products being commercialized in Japan, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across neurology, GI and immunology, metabolic disorders and rare diseases, and leverages the power of our unique and industry leading GPCR-targeted structure-based drug discovery NxWave™ platform to provide a sustainable source of best- or first-in-class candidates. Nxera employs over 350 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsKentaro Tahara, VP Investor Relations and Corporate StrategyShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager+81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@ MEDiSTRAVA (for International Media)Mark Swallow, Frazer Hall, Erica Hollingsworth+44 (0)203 928 6900 | Nxera@ Forward-looking statementsThis press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or in to access your portfolio
Yahoo
25-03-2025
- Health
- Yahoo
Tempero Bio gets $70M to advance substance abuse treatment
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Tempero Bio, a biotechnology company based in Oakland, California, has secured $70 million to advance a drug it's developing into mid-stage testing for cocaine and alcohol use disorders. The Series B round, announced by Tempero Monday, will support two Phase 2 trials of the drug, called TMP-301. The biotech will also use the funds to prepare for late-stage studies as well as to explore additional indications and formulations. The round was led by investor 8VC, and also involved Khosla Ventures and Aditum Bio, among others. A relatively new investor in biotech, Aditum previously backed Versanis Bio, an obesity drug developer acquired by Eli Lilly in 2023. The investment firm is run by former Novartis CEO Joe Jimenez and Mark Fishman, formerly head of Novartis Institutes for BioMedical Research. Aditum launched Tempero in 2020 via a partnership with the pharmaceutical company Sosei Heptares, now called Nxera Pharma. Nxera licensed TMP-301 to Tempero in exchange for an upfront payment and equity stake, while Aditum put up Tempero's initial funding. According to Tempero, TMP-301 is designed to 'address neurobiological basis of addiction' by reducing excessive signaling via a neurotransmitter called glutamate. More specifically, TMP-301 modulates the metabotropic glutamate receptor 5, which is involved in central nervous system function. Tempero said the drug showed potential in preclinical models of opiate, alcohol and cocaine use disorders. It has been tested in about 80 healthy individuals as part of a Phase 1 study. 'Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year. We urgently need more effective treatments to help patients and families with these diseases,' Tempero CEO Ricardo Dolmetsch said in a statement. While psychiatry drugs have regained investor and drugmaker attention in recent years, the pipeline of novel treatments for substance use disorders remains thin. One new area of promise is the GLP-1 drugs currently used for diabetes and weight loss. Their makers are now studying their effects in curbing alcohol use. Recommended Reading New Biogen CEO seeks to 'redefine' company after challenging year Sign in to access your portfolio
